問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間:2023-09-19

謝昀蓁Hsieh, Yun-Cheng
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月

篩選

List

48Cases

2025-02-03 - 2029-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Injectable frozen powder

Participate Sites
5Sites

Recruiting5Sites

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)
  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    Intravenous drip injection

Participate Sites
10Sites

Recruiting10Sites

2019-11-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2027-05-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-04-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-08-31 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2022-07-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-10-26 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2025-11-01 - 2031-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2020-06-26 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5